IP Library Granted Patent US 10,675,261
Granted Patent B2
US 10,675,261 · App. 16/133,458 · Granted Jun 9, 2020

Methods and compositions to inhibit dependence on opioids

Inventors: Jacqueline M. Iversen (Lloyd Harbor, NY); Thomas A. Dahl (Guilford, CT)
Assignee: SEN-JAM Pharmaceutical LLC
A61K31/192A61K9/0056A61K9/0058A61P25/36A61K31/4535A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,675,261
App. No.
16/133,458
Granted
Jun 9, 2020
Kind
B2
Abstract

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

Claims (25)

1. A method of inhibiting dependence to an opioid by a human subject in need thereof, comprising:

administering an effective amount of a pharmaceutical composition to the subject during opioid therapy, wherein the pharmaceutical composition comprises:

a) a non-steroidal anti-inflammatory drug (NSAID); and

b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof;

wherein dependence to an opioid is inhibited in the human subject,

wherein the opioid is selected from the group consisting of: opium, heroin, morphine, codeine, thebaine, hydrocodone, oxycodone, fentanyl, methadone, pethidine and hydromorphone.

2. The method of claim 1 wherein the NSAID is selected from the group consisting of: aspirin, ibuprofen, naproxen, diclofenac, diflunisal, etodolac, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin.

3. The method of claim 1 wherein the NSAID is ibuprofen and the co-agent is fexofenadine.

4. The method of claim 1 wherein the amount of ibuprofen is about 150 mg to about 900 mg, and the amount of fexofenadine is about 60 mg to about 180 mg.

5. The method of claim 1 wherein the ibuprofen and the fexofenadine is combined in one unit dose.

6. The method of claim 1 wherein the ibuprofen and the fexofenadine is in the form of a tablet, lozenge or chewing gum.

7. The method of claim 1 wherein the NSAID is ibuprofen and the co-agent is ketotifen.

8. The method of claim 1 wherein the amount of ibuprofen is about 1200 mg to about 1600 mg, and the amount of ketotifen is about 0.5 mg to about 3 mg.

9. The method of claim 2 wherein the daily dose of ibuprofen is about 2400 mg to about 3200 mg, and the daily dose of ketotifen is about 2 mg.

10. The method of claim 9 wherein the ibuprofen and the ketotifen is combined in one unit dose.

11. The method of claim 10 wherein the ibuprofen and the ketotifen is in the form of a tablet, lozenge or chewing gum.

12. A method of inhibiting dependence to an opioid by a human subject in need thereof, comprising:

administering to the subject an effective amount of a pharmaceutical composition during an opioid therapy, wherein the pharmaceutical composition consists essentially of:

a) about 1200 mg to about 1600 mg of ibuprofen, and

b) about 0.5 mg to about 3 mg ketotifen,

wherein dependence to an opioid is inhibited in the human subject,

wherein the opioid is selected from the group consisting, of: opium, heroin, morphine, codeine, thebaine, hydrocodone, oxycodone, fentanyl, methadone, pethidine and hydromorphone.

13. The method of claim 12 wherein a daily dose of ibuprofen is about 2400 mg to about 3200 mg, and the a daily dose of ketotifen is about 2 mg.

14. The method of claim 12 wherein the ibuprofen and the ketotifen are combined in one unit dose.

15. The method of claim 12 wherein the ibuprofen and the ketotifen are in the form of a tablet, lozenge or chewing gum.

Assignments (2)
MERGER Recorded Sep 12, 2024
From: SEN-JAM PHARMACEUTICAL LLC
To: SEN-JAM PHARMACEUTICAL INC.
Reel/Frame 068948/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2018
From: IVERSEN, JACQUELINE M; DAHL, THOMAS A.
To: SEN-JAM PHARMACEUTICAL LLC
Reel/Frame 047592/0881 →
Continuity (2)
Provisional Application 62560046 · Sep 18, 2017
Related Publication 20190083431A1 · Mar 21, 2019